Progress in Alzheimer’s Disease: Biological Definitions, Early Detection, and Clinical Pathways

Executive Summary

Recent scientific and clinical advancements have fundamentally shifted the understanding of Alzheimer’s disease (AD) from a symptom-based clinical diagnosis to a biological process detectable decades before cognitive decline. Key takeaways from recent research and revised guidelines include:

• Biological Reclassification: The 2024 revised criteria define AD through biomarkers (AT1T2NISV framework), allowing for diagnosis in cognitively unimpaired individuals based on core biological markers.
• Two-Phase Disease Progression: AD is now understood to occur in two distinct "epochs": a long, silent first phase affecting specific inhibitory neurons, followed by a destructive second phase where symptoms and protein accumulation accelerate.
• Novel Early Warning Signs: Enlarged perivascular spaces ("clogged brain drains") visible on standard MRI scans and "Mild Behavioral Impairment" (MBI)—specifically complex clusters of neuropsychiatric symptoms—serve as critical early indicators of AD risk.
• Clinical Intervention Realities: While new monoclonal antibody therapies like lecanemab offer a reduction in the rate of cognitive decline, strict eligibility criteria and the risk of Amyloid-Related Imaging Abnormalities (ARIA) significantly limit the number of qualifying patients.

--------------------------------------------------------------------------------

1. The Biological Definition of Alzheimer’s Disease

The 2024 revised criteria by the Alzheimer’s Association Workgroup have transitioned AD from a clinical-syndrome definition to a purely biological one. This "bridge between research and clinical care" establishes that AD exists when specific biological processes are present, regardless of whether symptoms are manifest.

The AT1T2NISV Biomarker Framework

Biomarkers are now categorized into a complex schema to track the disease's multi-faceted progression:

Category

Description

Specific Markers

A

Amyloid Proteinopathy

Fluid Aβ42, Amyloid PET

T1

Early Tau Pathophysiology

Phosphorylated and secreted AD tau (CSF/Plasma)

T2

Advanced Tau Proteinopathy

Non-phosphorylated mid-region fragments; correlates with Tau PET

N

Neurodegeneration/Injury

Fluid neurofilament light chain (Nfl), MRI markers

I

Inflammation

Astrocyte reactivity (GFAP), microglial reactivity (sTREM2)

S

α-synuclein

Alpha-synuclein seed amplification assay (Non-AD copathology)

V

Vascular Brain Injury

Neuroimaging measures (Non-AD copathology)

Key Highlight: A single abnormal "Core 1" biomarker (A or T1) is now considered sufficient to diagnose Alzheimer’s disease, even in individuals with normal cognitive function.

--------------------------------------------------------------------------------

2. Pathological Progression: The Two-Phase Model

NIH-funded brain mapping research suggests that AD damages the brain in two distinct phases, or "epochs," rather than a continuous linear decline.

Phase 1: The Silent Epoch

• Characteristics: Occurs slowly and "quietly" before memory problems appear.
• Key Discovery: The earliest damage involves the death of somatostatin (SST) inhibitory neurons. Traditionally, research focused on excitatory neurons, but SST cell loss may be the actual trigger for the neural circuit problems that lead to the disease.
• Other Changes: Slow accumulation of plaques, immune system activation, and damage to cellular insulation.

Phase 2: The Destructive Epoch

• Characteristics: Widely destructive and coincides with the rapid accumulation of plaques and tangles.
• Clinical Impact: This phase aligns with the appearance of clinical symptoms and memory loss.

--------------------------------------------------------------------------------

3. Early Detection Indicators

Clogged Brain “Drains” (MRI Signals)

Researchers at Nanyang Technological University discovered that "enlarged perivascular spaces" (EPVS) serve as early warning signs.

• Mechanism: These are small channels surrounding blood vessels that drain toxic waste, including beta amyloid and tau. When the waste removal system fails, these spaces enlarge.
• Visibility: These blockages are easily identifiable on standard MRI scans performed during routine cognitive evaluations.
• Significance: In many cases, these "clogged drains" signal AD risk earlier than white matter damage, particularly in Asian populations where traditional genetic risk factors (like APOE-E4) may be less prevalent.

Mild Behavioral Impairment (MBI)

MBI represents the neurobehavioral axis of pre-dementia risk. It is characterized by the late-life emergence of sustained neuropsychiatric symptoms across five domains:

1. Decreased Motivation: Apathy and indifference.
2. Affective Dysregulation: Depression, anxiety, and euphoria.
3. Impulse Dyscontrol: Agitation, irritability, and aggression.
4. Social Inappropriateness: Disinhibition.
5. Abnormal Perception/Thought Content: Delusions and hallucinations.

The "Complex" Risk Factor: Research indicates that patients with "complex" MBI—showing multiple co-occurring symptoms—have a significantly higher hazard ratio (2.541) for progressing to AD compared to those with only affective dysregulation or no symptoms. This complex state is also linked to measurable cortical thinning in the temporal, parietal, and frontal regions.

--------------------------------------------------------------------------------

4. Clinical Therapies and Eligibility

The "Amyloid Cascade Hypothesis" posits that AD begins with amyloid (A) plaques, followed by tau (T) tangles, and finally neurodegeneration (N). New monoclonal antibody therapies target this cascade by modulating the clearance of brain amyloid.

Lecanemab and Aducanumab

• Lecanemab Efficacy: In large-scale trials, lecanemab showed a 27% reduction in the rate of clinical progression (CDR-sb scores) over 18 months compared to a placebo.
• Eligibility Paradox: Despite the approval for MCI and mild AD, strict exclusion criteria mean very few patients qualify. A Mayo Clinic study found that only 8% of patients with MCI or mild dementia met lecanemab's inclusion/exclusion criteria.

Amyloid-Related Imaging Abnormalities (ARIA)

The primary safety concern for these therapies is ARIA, which includes:

• ARIA-E: Edema (swelling).
• ARIA-H: Microhemorrhages or hemosiderin deposits.

Risk Factors and Management:

• APOE-ε4: Homozygous carriers of the APOE-ε4 gene are at higher risk for ARIA.
• Monitoring: Frequent MRI scans (e.g., weeks 7, 15, and 23 for aducanumab) are required to track radiographic signs.
• Contraindications: Use of anticoagulants, bleeding disorders, or having more than 10 micro-hemorrhages since starting treatment typically disqualifies a patient from continuing therapy.

Differential Diagnosis

Therapies like lecanemab are only for AD. Patients do not qualify if their cognitive decline is caused by:

• Vascular Cognitive Impairment: Often involves gait apraxia and hyperreflexia.
• Frontotemporal Dementia: Characterized by early behavioral changes and severe apathy.
• Primary Progressive Aphasia: Focused on language problems and non-AD self-care issues.
• Dementia with Lewy Bodies: Distinguished by visual hallucinations and parkinsonism.

--------------------------------------------------------------------------------

5. Important Quotes and Expert Insights

"Identifying these brain anomalies on routine MRI scans could complement existing methods to detect Alzheimer's earlier, without having to do and pay for additional tests." — Assoc. Prof. Nagaendran Kandiah, NTU Singapore

"The ability to detect these early changes means that, for the first time, we can see what is happening to a person's brain during the earliest periods of the disease." — Dr. Richard J. Hodes, Director, NIH National Institute on Aging

"Whether current science is strong enough to support a purely biological definition of AD in vivo remains controversial... biomarkers alone cannot reliably predict the progression from unimpaired cognition to AD phenotypes." — Dr. Yi-Ting Lin, National Taiwan University Hospital

"Patients with MCI and mild AD dementia need to be carefully screened before being considered for treatment with anti-amyloid Rx." — Dr. Linda A. Hershey, OU College of Medicine